Jones Jeb, Manley Georgia, Glynn Tiffany R, Wall Kristin M, Baral Stefan D, Harris E Danny, Benkeser David, Sullivan Patrick S
Department of Epidemiology, Emory University, Atlanta, GA, United States.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
JMIR Res Protoc. 2025 Jul 23;14:e69540. doi: 10.2196/69540.
BACKGROUND: Gay and bisexual men who have sex with men (MSM) in the rural United States are less likely to test for HIV and sexually transmitted infections (STIs) and use pre-exposure prophylaxis (PrEP) compared to urban MSM. Given the challenges in building brick-and-mortar facilities serving the sexual health needs of MSM in rural communities, there is a need to evaluate digital engagement strategies. Combine is a smartphone app designed to provide HIV prevention information and resources to MSM that may be particularly well suited to support rural MSM. HealthMindr, an app from which Combine is adapted, has previously been shown to increase HIV testing and PrEP uptake among urban MSM. Because rural MSM face additional barriers to accessing HIV prevention services, a motivational interview (MI) focused on HIV prevention strategies might enhance the effectiveness of Combine to increase uptake of HIV testing, STI testing, and PrEP. OBJECTIVE: This study aims to determine the effectiveness of the Combine app to increase HIV testing, STI testing, and PrEP initiation among rural cisgender MSM. We will also assess the effectiveness of 2 adjunctive interventions: the availability of free HIV and STI self-test kits and the offering of an MI. METHODS: In this type 2 hybrid effectiveness-implementation randomized controlled trial, we will assess the effectiveness of Combine to increase HIV testing, STI testing, and PrEP initiation among rural MSM across the Southern United States. A total of 464 men will be recruited and randomized to 1 of the 4 arms. Participants in all 4 arms will have access to most app features (eg, health resources, quizzes, health care provider locators, and ordering free condoms and lubricants). Using a 2×2 factorial design, half (232/464, 50%) of the participants will be randomized to receive access to free at-home HIV and STI self-test kits and half (232/464, 50%) will be randomized to receive an MI. Participants will complete surveys every 6 months to allow for assessment of self-reported outcomes: app use, HIV testing, STI testing, and PrEP initiation over the 24-month follow-up period. Self-reported PrEP uptake will be verified by dried blood spot testing or uploading a photograph of a PrEP prescription. RESULTS: Participant recruitment began in March 2024. As of July 2025, 395 participants have been enrolled and randomized. Recruitment is expected to be completed by December 2025. CONCLUSIONS: This trial will determine whether the Combine app increases HIV testing, STI testing, and PrEP uptake among rural MSM in the Southern United States. It will also provide critical information about the most effective strategies for implementing digital health interventions for rural MSM. TRIAL REGISTRATION: ClinicalTrials.gov NCT06205368; https://clinicaltrials.gov/study/NCT06205368. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/69540.
背景:与城市男男性行为者相比,美国农村地区的男同性恋者和双性恋男性与男性发生性行为者(MSM)进行艾滋病毒和性传播感染(STIs)检测以及使用暴露前预防(PrEP)的可能性较小。鉴于为农村社区有性健康需求的男男性行为者建设实体设施存在挑战,有必要评估数字参与策略。Combine是一款智能手机应用程序,旨在为男男性行为者提供艾滋病毒预防信息和资源,可能特别适合支持农村男男性行为者。HealthMindr是一款被Combine改编的应用程序,此前已被证明可提高城市男男性行为者的艾滋病毒检测率和PrEP使用率。由于农村男男性行为者在获取艾滋病毒预防服务方面面临额外障碍,聚焦于艾滋病毒预防策略的动机性访谈(MI)可能会提高Combine在增加艾滋病毒检测、性传播感染检测和PrEP使用方面的有效性。 目的:本研究旨在确定Combine应用程序在增加美国农村顺性别男男性行为者的艾滋病毒检测、性传播感染检测和PrEP启动方面的有效性。我们还将评估两种辅助干预措施的有效性:提供免费的艾滋病毒和性传播感染自检试剂盒以及提供动机性访谈。 方法:在这项2型混合有效性 - 实施随机对照试验中,我们将评估Combine在增加美国南部农村男男性行为者的艾滋病毒检测、性传播感染检测和PrEP启动方面的有效性。总共将招募464名男性,并随机分配到4个组中的1个组。所有4个组的参与者都可以使用大多数应用程序功能(例如,健康资源、测验、医疗保健提供者定位器以及订购免费避孕套和润滑剂)。采用2×2析因设计,一半(232/464,50%)的参与者将被随机分配以获得免费的家用艾滋病毒和性传播感染自检试剂盒,另一半(232/464,50%)将被随机分配接受动机性访谈。参与者将每6个月完成一次调查,以便评估自我报告的结果:在24个月的随访期内应用程序的使用情况、艾滋病毒检测、性传播感染检测和PrEP启动情况。自我报告的PrEP使用情况将通过干血斑检测或上传PrEP处方照片进行核实。 结果:参与者招募于2024年3月开始。截至2025年7月,已有395名参与者登记并随机分组。预计招募工作将于2025年12月完成。 结论:该试验将确定Combine应用程序是否能增加美国南部农村男男性行为者的艾滋病毒检测、性传播感染检测和PrEP使用。它还将提供有关为农村男男性行为者实施数字健康干预的最有效策略的关键信息。 试验注册:ClinicalTrials.gov NCT06205368;https://clinicaltrials.gov/study/NCT06205368。 国际注册报告标识符(IRRID):DERR1-10.2196/69540。
Cochrane Database Syst Rev. 2008-7-16
Mhealth. 2021-4-20
Mhealth. 2021-4-20